Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-7684A-005 | Other Identifier | MSD | |
| jRCT2031210335 | Registry Identifier | jRCT | |
| KEYVIBE-005 | Other Identifier | MSD | |
| 2023-505284-36-00 | Registry Identifier | EU CT | |
| U1111-1291-4290 | Registry Identifier | UTN | |
| 2021-001009-56 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pembrolizumab/Vibostolimab Co-Formulation | Experimental | Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy. |
|
| Pembrolizumab | Experimental | Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles. |
|
| Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort) | Experimental | Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib. |
|
| Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort) | Experimental | Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW <60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pembrolizumab/Vibostolimab Co-Formulation | Biological | Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W |
|
| Measure | Description | Time Frame |
|---|---|---|
| Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) | ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 will be presented. | Up to approximately 2 years |
| Progression-Free Survival (PFS) per RECIST 1.1 as Assessed by BICR | PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. | Up to approximately 2 years |
| ORR per RECIST 1.1 as Assessed by Investigator in Participants with Selected Solid Tumors | ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 will be presented. | Up to approximately 2 years |
| PFS per RECIST 1.1 as Assessed by Investigator at 9 months | PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival (OS) | OS is defined as the time from randomization to death due to any cause. | Up to approximately 5.5 years |
| PFS per RECIST 1.1 as Assessed by Investigator | PFS is defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by investigator will be presented. |
Not provided
Inclusion Criteria:
One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:
Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.
Adequately controlled blood pressure (BP) with or without antihypertensive medications.
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).
Male participants must agree to follow contraceptive guidance.
Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.
Adequate organ function.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alaska Womens Cancer Care ( Site 1016) | Anchorage | Alaska | 99508 | United States | ||
| City of Hope Comprehensive Cancer Center ( Site 1001) |
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
| Plain Language Summary | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Participants with locally recurrent unresectable or metastatic cervical cancer whose tumors express programmed cell death 1 ligand 1 (PD-LI) and have a combined positive score (CPS) ≥1 will be randomly assigned to treatment with either pembrolizumab/vibostolimab co-formulation or pembrolizumab only. The other study intervention arms will be assigned to participants depending on the selected cancer type.
Not provided
Not provided
Not provided
Not provided
|
| Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin | Experimental | Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin. |
|
| Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel | Experimental | Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel. |
|
| Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin | Experimental | Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin |
|
| Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab | Experimental | Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab. |
|
| Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin | Experimental | Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin. |
|
|
| Pembrolizumab | Biological | Pembrolizumab 200 mg administered via IV infusion Q3W. |
|
|
| Lenvatinib | Drug | Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD |
|
|
| 5-Fluorouracil | Drug | 5-FU 800 mg/m^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles |
|
|
| Cisplatin | Drug | Cisplatin administered via IV infusion |
|
|
| Paclitaxel | Drug | Paclitaxel administered via IV infusion at investigator's choice of dose |
|
|
| Gemcitabine | Drug | Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity |
|
| Carboplatin | Drug | Carboplatin administered via IV infusion at investigator's choice of dose and frequency |
|
| Docetaxel | Drug | For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles |
|
| Bevacizumab | Drug | Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles |
|
| Capecitabine | Drug | Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles |
|
| Oxaliplatin | Drug | Oxaliplatin administered via IV infusion Q3W up to 35 cycles |
|
| 9 months |
| PFS per RECIST 1.1 as Assessed by Investigator at 12 months | PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. | 12 months |
| Up to approximately 2 years |
| Duration of Response (DOR) per RECIST 1.1 as Assessed by BICR | For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR will be presented. | Up to approximately 2 years |
| DOR per RECIST 1.1 as Assessed by Investigator | For participants who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until PD or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by investigator will be presented. | Up to approximately 2 years |
| ORR per RECIST 1.1 as Assessed by Investigator | ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 will be presented. | Up to approximately 2 years |
| PFS per RECIST 1.1 as Assessed by Investigator in Participants with Cervical Cancer | PFS is defined as the time from first dose of study treatment to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by investigator will be presented. | Up to approximately 2 years |
| Change from Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) | The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented. | Baseline and up to approximately 2 years |
| Change from Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) | The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented. | Baseline and up to approximately 2 years |
| Number of Participants Who Experienced One or More Adverse Events (AEs) | An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. | Up to approximately 2 years |
| Number of Participants Who Discontinued Study Intervention Due to an AE | An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. | Up to approximately 2 years |
| Duarte |
| California |
| 91010 |
| United States |
| University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente | Orange | California | 92868-3201 | United States |
| Karmanos Cancer Institute ( Site 1007) | Detroit | Michigan | 48201 | United States |
| Memorial Sloan Kettering - Basking Ridge ( Site 1023) | Basking Ridge | New Jersey | 07920 | United States |
| Memorial Sloan Kettering - Monmouth ( Site 1022) | Middletown | New Jersey | 07748 | United States |
| Memorial Sloan Kettering - Bergen ( Site 1025) | Montvale | New Jersey | 07645 | United States |
| Memorial Sloan Kettering- Commack ( Site 1021) | Commack | New York | 11725 | United States |
| Memorial Sloan Kettering - Westchester ( Site 1020) | Harrison | New York | 10604 | United States |
| Memorial Sloan Kettering Cancer Center ( Site 1002) | New York | New York | 10065 | United States |
| Memorial Sloan Kettering - Nassau ( Site 1026) | Uniondale | New York | 11553 | United States |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024) | Tulsa | Oklahoma | 74146 | United States |
| Sanford Cancer Center-Gynecologic Oncology ( Site 1015) | Sioux Falls | South Dakota | 57104 | United States |
| Houston Methodist Hospital ( Site 1017) | Houston | Texas | 77030 | United States |
| Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051) | Kingston | Ontario | K7L 2V7 | Canada |
| Princess Margaret Cancer Centre ( Site 1056) | Toronto | Ontario | M5G 2M9 | Canada |
| James Lind Centro de Investigacion del Cancer ( Site 1404) | Temuco | Araucania | 4800827 | Chile |
| FALP-UIDO ( Site 1401) | Santiago | Region M. de Santiago | 7500921 | Chile |
| Oncovida ( Site 1405) | Santiago | Region M. de Santiago | 7510032 | Chile |
| Bradfordhill-Clinical Area ( Site 1402) | Santiago | Region M. de Santiago | 8420383 | Chile |
| Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422) | Medellín | Antioquia | 050030 | Colombia |
| Clinica de la Costa S.A.S. ( Site 1421) | Barranquilla | Atlántico | 080020 | Colombia |
| Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425) | Bogotá | Cundinamarca | 111511 | Colombia |
| Oncologos del Occidente ( Site 1424) | Pereira | Risaralda Department | 661001 | Colombia |
| Fundación Cardiovascular de Colombia ( Site 1423) | Piedecuesta | Santander Department | 681017 | Colombia |
| CENTRE LEON BERARD-Medical oncology ( Site 1151) | Lyon | Auvergne-Rhône-Alpes | 69373 Cedex 08 | France |
| Centre Georges François Leclerc ( Site 1155) | Dijon | Cote-d Or | 21079 | France |
| Institut Regional du Cancer Montpellier ( Site 1157) | Montpellier | Herault | 34298 | France |
| Gustave Roussy-medicine departement ( Site 1153) | Villejuif | Paris | 94800 | France |
| Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156) | Avignon | Vaucluse | 84000 | France |
| Institut Curie ( Site 1152) | Paris | 75248 | France |
| Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180) | Heidelberg | Baden-Wurttemberg | 69120 | Germany |
| Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne | Tübingen | Baden-Wurttemberg | 72076 | Germany |
| Klinikum der Universität München Großhadern ( Site 1176) | München | Bavaria | 81337 | Germany |
| Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172) | Düsseldorf | North Rhine-Westphalia | 40225 | Germany |
| Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171) | Berlin | 12203 | Germany |
| Rambam Health Care Campus-Oncology ( Site 1141) | Haifa | 3109601 | Israel |
| Hadassah Medical Center-Oncology ( Site 1142) | Jerusalem | 9112001 | Israel |
| Sheba Medical Center-ONCOLOGY ( Site 1144) | Ramat Gan | 5265601 | Israel |
| Sourasky Medical Center-Oncology ( Site 1143) | Tel Aviv | 6423906 | Israel |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136) | Rome | Lazio | 00168 | Italy |
| Ospedale San Raffaele-Oncologia Medica ( Site 1135) | Milan | Lombardy | 20132 | Italy |
| Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138) | Rozzano | Milano | 20089 | Italy |
| Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( | Milan | 20141 | Italy |
| Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134) | Naples | 80131 | Italy |
| Aichi Cancer Center Hospital ( Site 1324) | Nagoya | Aichi-ken | 464-8681 | Japan |
| National Cancer Center Hospital East ( Site 1321) | Kashiwa | Chiba | 277-8577 | Japan |
| Osaka International Cancer Institute ( Site 1323) | Osaka | 541-8567 | Japan |
| National Cancer Center Hospital ( Site 1322) | Tokyo | 104-0045 | Japan |
| Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121) | Amsterdam | North Holland | 1066CX | Netherlands |
| Erasmus Medisch Centrum-Medical Oncology ( Site 1122) | Rotterdam | South Holland | 3015 GD | Netherlands |
| Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101 | Warsaw | Masovian Voivodeship | 02-781 | Poland |
| Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103) | Gdansk | Pomeranian Voivodeship | 80-952 | Poland |
| Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104) | Koszalin | West Pomeranian Voivodeship | 75-581 | Poland |
| Seoul National University Hospital-Internal Medicine ( Site 1312) | Seoul | 03080 | South Korea |
| Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311) | Seoul | 03722 | South Korea |
| Asan Medical Center ( Site 1313) | Seoul | 05505 | South Korea |
| Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113) | Hospitalet | Barcelona | 08907 | Spain |
| HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117) | Pozuelo de Alarcón | Madrid | 28223 | Spain |
| Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111) | Madrid | Madrid, Comunidad de | 28034 | Spain |
| Clinica Universidad de Navarra-Medical Oncology ( Site 1118) | Madrid | 28027 | Spain |
| HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114) | Seville | 41013 | Spain |
| NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302) | Tainan | 704 | Taiwan |
| National Taiwan University Hospital-Oncology ( Site 1301) | Taipei | 10002 | Taiwan |
| Mackay Memorial Hospital ( Site 1305) | Taipei | 10449 | Taiwan |
| Chang Gung Medical Foundation-Linkou Branch ( Site 1304) | Taoyuan | 333 | Taiwan |
| Istanbul Universitesi Cerrahpasa ( Site 1203) | Istanbul- Fatih | Istanbul | 34098 | Turkey (Türkiye) |
| Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201) | Adana | 01250 | Turkey (Türkiye) |
| Hacettepe Universitesi-oncology hospital ( Site 1209) | Ankara | 06230 | Turkey (Türkiye) |
| Ankara City Hospital-Medical Oncology ( Site 1202) | Ankara | 06800 | Turkey (Türkiye) |
| Trakya University-Medical Oncology ( Site 1207) | Edirne | 22030 | Turkey (Türkiye) |
| Acibadem Universitesi Atakent Hastanesi ( Site 1208) | Istanbul | 34303 | Turkey (Türkiye) |
| TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204) | Istanbul | 34722 | Turkey (Türkiye) |
| ID | Term |
|---|---|
| D002583 | Uterine Cervical Neoplasms |
| D016889 | Endometrial Neoplasms |
| D000077195 | Squamous Cell Carcinoma of Head and Neck |
| D005706 | Gallbladder Neoplasms |
| D018281 | Cholangiocarcinoma |
| D004938 | Esophageal Neoplasms |
| D064726 | Triple Negative Breast Neoplasms |
| D006528 | Carcinoma, Hepatocellular |
| D001749 | Urinary Bladder Neoplasms |
| D010051 | Ovarian Neoplasms |
| D013274 | Stomach Neoplasms |
| C565324 | Parkinson Disease 4, Autosomal Dominant Lewy Body |
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
| D002294 | Carcinoma, Squamous Cell |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D006258 | Head and Neck Neoplasms |
| D001661 | Biliary Tract Neoplasms |
| D004067 | Digestive System Neoplasms |
| D001660 | Biliary Tract Diseases |
| D004066 | Digestive System Diseases |
| D005705 | Gallbladder Diseases |
| D000230 | Adenocarcinoma |
| D005770 | Gastrointestinal Neoplasms |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
| D001943 | Breast Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D008113 | Liver Neoplasms |
| D008107 | Liver Diseases |
| D014571 | Urologic Neoplasms |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D004701 | Endocrine Gland Neoplasms |
| D010049 | Ovarian Diseases |
| D000291 | Adnexal Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
| D013272 | Stomach Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C582435 | pembrolizumab |
| C531958 | lenvatinib |
| D005472 | Fluorouracil |
| D002945 | Cisplatin |
| D017239 | Paclitaxel |
| D000068196 | Albumin-Bound Paclitaxel |
| D000093542 | Gemcitabine |
| D016190 | Carboplatin |
| D000077143 | Docetaxel |
| D000068258 | Bevacizumab |
| D000069287 | Capecitabine |
| D000077150 | Oxaliplatin |
| ID | Term |
|---|---|
| D014498 | Uracil |
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017672 | Nitrogen Compounds |
| D017671 | Platinum Compounds |
| D043823 | Taxoids |
| D043822 | Cyclodecanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D004224 | Diterpenes |
| D013729 | Terpenes |
| D000418 | Albumins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D003841 | Deoxycytidine |
| D003562 | Cytidine |
| D011741 | Pyrimidine Nucleosides |
| D056831 | Coordination Complexes |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D003853 | Deoxyribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
Not provided
Not provided